Topsalysin

Summary

Topsalysin (CHEMBL2364656) is a phase-3 clinical-stage unknown; indicated across 2 conditions including benign prostatic hyperplasia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2364656
Name	Topsalysin
Type	Unknown
Max phase	3

Also known as: PRX-302, PRX302, Topsalisina, Topsalysin, Topsalysine, TOPSALYSIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
benign prostatic hyperplasia	3	MONDO:0010811	EFO:0000284

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE2	4
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01966614	PHASE3	COMPLETED	Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH
NCT00686088	PHASE2	COMPLETED	An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy
NCT00889707	PHASE2	COMPLETED	Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia
NCT01454349	PHASE1/PHASE2	COMPLETED	Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)
NCT02499848	PHASE2	COMPLETED	Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer
NCT03081481	PHASE2	COMPLETED	Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).